{
    "clinical_study": {
        "@rank": "31661", 
        "arm_group": {
            "arm_group_label": "HAVG graft", 
            "arm_group_type": "Experimental", 
            "description": "HAVG graft implantation to study participants."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered\n      vascular prosthesis, the Human Acellular Vascular Graft, HAVG.\n\n      The HAVG is intended as an alternative to synthetic materials and to autologous grafts in\n      the creation of vascular access for dialysis."
        }, 
        "brief_title": "Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "End-stage Renal Disease", 
            "Kidney Failure, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "The HAVG is a sterile, non-pyrogenic, acellular tubular graft composed of human collagens\n      and other natural extra-cellular matrix proteins. Upon implantation, it is anticipated\n      (based on pre-clinical studies) that the collagen-based matrix comprising the graft will be\n      infiltrated with host cells and re-modeled by the host. This will result in a vascular\n      structure more similar to the histological composition of the native vascular tissue that\n      may improve graft longevity and be less likely to become infected."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with end stage renal disease (ESRD) who are not, or who are no longer,\n             candidates for creation of an autogenous AV fistula and therefore need placement of\n             an AV graft in the upper extremity to start or maintain hemodialysis therapy\n\n          -  Patients between 18 and 75 years old, inclusive\n\n          -  Suitable anatomy for implantation of straight forearm grafts or curved upper arm\n             grafts (arterial anastomosis to radial or brachial artery, venous anastomosis to\n             either brachial cephalic or very central basilica vein)\n\n          -  Hemoglobin \u22658g/dL and platelet count \u2265100,000/mm3 prior to Day 1\n\n          -  Other hematological and biochemical parameters within a range consistent with ESRD\n             and acceptable for the administration of general anesthesia prior to Day 1\n\n          -  Adequate liver function, defined as serum bilirubin \u22641.5 mg/dL; GGT, AST, ALT, and\n             alkaline phosphatase \u22642x upper limit of normal or INR \u2264 1.5 prior to Day 1.\n\n          -  Ability to communicate meaningfully with investigative staff, competence to give\n             written informed consent, and ability to comply with entire study procedures\n\n          -  Able and willing to give informed consent\n\n          -  Life expectancy of at least 1 year\n\n        Exclusion Criteria:\n\n          -  History or evidence of severe cardiac disease (NYHA Functional Class III or IV),\n             myocardial infarction within six months of study entry (Day 1), ventricular\n             tachyarrhythmias requiring continuing treatment, or unstable angina\n\n          -  History or evidence of severe peripheral vascular disease in the upper limbs\n\n          -  Known or suspected central vein obstruction on the side of planned graft implantation\n\n          -  Stroke within six (6) months of study entry (Day 1)\n\n          -  Treatment with any investigational drug or device within 60 days prior to study entry\n             (Day 1)\n\n          -  Treatment with vitamin K-antagonists or direct thrombin inhibitors within the\n             previous month to study entry (Day 1)\n\n          -  All patients (including both female patients of childbearing potential and male\n             patients with childbearing potential partners) who do not use a highly effective\n             method of birth control (failure rate less than 1% per year when used consistently\n             and correctly), e.g. implants, injectables, combined oral contraceptives in\n             combination with a barrier method, some intrauterine contraceptive devices, sexual\n             abstinence, or a vasectomized partner\n\n          -  Active diagnosis of cancer within the previous year\n\n          -  Immunodeficiency including AIDS / HIV\n\n          -  Documented hypercoagulable state or history of 2 or more DVTs or other spontaneous\n             intravascular thrombotic events\n\n          -  Bleeding diathesis\n\n          -  Active autoimmune disease\n\n          -  Previous PTFE graft in the operative limb unless the HAVG can be placed more\n             proximally than the previous failed graft\n\n          -  More than 1 failed PTFE graft in the operative limb\n\n          -  Active local or systemic infection (WBC > 15,000/mm3)\n\n          -  Patients receiving a forearm graft with which crosses the elbow\n\n          -  Patients receiving an upper arm graft with arterial anastomosis to the axillary\n             artery or venous anastomosis to the axillary vein\n\n          -  Patients receiving a lower extremity AV access\n\n          -  Known serious allergy to aspirin or penicillin\n\n          -  Any other condition which in the judgment of the investigator would preclude adequate\n             evaluation of the safety and efficacy of the HAVG\n\n          -  Previous enrollment in this study\n\n          -  Employees of the sponsor or patients who are employees or relatives of the\n             investigator\n\n          -  PRA > 20% (first 10 patients only)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744418", 
            "org_study_id": "CLN-PRO-V001"
        }, 
        "intervention": {
            "arm_group_label": "HAVG graft", 
            "description": "Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.", 
            "intervention_name": "HAVG graft implantation", 
            "intervention_type": "Device", 
            "other_name": "Human Acellular Vascular Graft"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ESRD", 
            "HEMODIALYSIS", 
            "CHRONIC RENAL INSUFFICIENCY", 
            "Renal Dialysis", 
            "Hemodiafiltration", 
            "Blood Vessel Prosthesis", 
            "Tissue-Engineered Vascular Graft", 
            "Vascular Prosthesis Implantation"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tomzubil@poczta.onet.pl", 
                    "last_name": "Tomasz Zubilewicz, Prof.MD PhD", 
                    "phone": "+48 81 5325", 
                    "phone_ext": "707"
                }, 
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland", 
                        "zip": "20-081"
                    }, 
                    "name": "Department of Vascular Surgery and Angiology at the Medical University Lublin"
                }, 
                "investigator": {
                    "last_name": "Tomasz Zubilewicz, Prof.MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j.k.szmidt@gmail.com", 
                    "last_name": "Jacek Szmidt, Prof.dr.hab.med.", 
                    "phone": "+48 22 599 24 67"
                }, 
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland", 
                        "zip": "02-097"
                    }, 
                    "name": "Independent Public Central Clinical Hospital in Warsaw; Department of General, Vascular and Transplant Surgery"
                }, 
                "investigator": {
                    "last_name": "Jacek Szmidt, Prof.dr.hab.med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "witkiewicz@wssk.wroc.pl", 
                    "last_name": "Wojciech Witkiewicz, Prof.Dr.Med.", 
                    "phone": "+48 71 32 70 336"
                }, 
                "facility": {
                    "address": {
                        "city": "Wroclaw", 
                        "country": "Poland", 
                        "zip": "51-124"
                    }, 
                    "name": "Regional Specialist Hospital in Wroclaw; Clinic of Vascular Surgery"
                }, 
                "investigator": {
                    "last_name": "Wojciech Witkiewicz, Prof.Dr.Med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease", 
        "overall_contact": {
            "email": "pilgrim@humacyte.com", 
            "last_name": "Alison J. Pilgrim, BM BCh Phil", 
            "phone": "+1 919 313 9633"
        }, 
        "overall_official": {
            "affiliation": "Humacyte, Inc.", 
            "last_name": "Alison J. Pilgrim, BM BCh Phil", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The incidence of aneurysm formation, anastomotic bleeding or rupture, graft infection and irritation/inflammation/infection at the implantation site will be tabulated by visit and overall.", 
                "measure": "HAVG safety & tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "At each visit within first 6 months after HAVG implantation."
            }, 
            {
                "description": "Determine the patency (primary, primary assisted and secondary) rate of the Humacyte HAVG.", 
                "measure": "HAVG patency rate", 
                "safety_issue": "No", 
                "time_frame": "At 6 months after HAVG  implantation."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744418"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assess changes in the PRA response over the 6 months after graft implantation.", 
                "measure": "PRA response", 
                "safety_issue": "Yes", 
                "time_frame": "At screening, day 15, 29, 57 and week 12, 26"
            }, 
            {
                "description": "Determine whether IgG antibodies to the extracellular matrix material are formed in response to implantation of the HAVG.", 
                "measure": "IgG antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "At screening, day 15, 29, 57 and week 12, 26"
            }, 
            {
                "description": "Determine the rates of interventions needed to maintain / restore patency in the graft.", 
                "measure": "Patency maintenance/restoration", 
                "safety_issue": "No", 
                "time_frame": "At each visit except screening."
            }, 
            {
                "description": "Patency rates (primary, primary assisted and secondary) at 12, 18 and 24 months.", 
                "measure": "HAVG patency rates", 
                "safety_issue": "No", 
                "time_frame": "At 12, 18, 24 months after HAVG implantation."
            }
        ], 
        "source": "Humacyte, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "FGK Clinical Research Sp. z o.o.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "FGK Clinical Research GmbH", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Humacyte, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}